EGFR and lip and oral cavity carcinoma: Two classes of new therapeutic agents directed against molecules involved in apoptosis pathway have been developed that can be used in combination with anti-EGFR therapy in oral cancers to overcome EGFR polymorphism based therapeutic resistance.